Skip to content

    Sexual Conditions Health Center

    Font Size

    'Female Libido' Pill May Not Be Worth It: Report

    Addyi carries host of serious side effects without delivering much more sexual satisfaction, review suggests

    WebMD News from HealthDay

    By Dennis Thompson

    HealthDay Reporter

    MONDAY, Feb. 29, 2016 (HealthDay News) -- The much-touted "female libido" pill seems to cause a host of serious side effects while failing to spark much additional passion in a woman's life, a new review suggests.

    Addyi (flibanserin) quadruples the risk of dizziness and sleepiness, more than doubles the chances of nausea, and increases the risk of fatigue by more than half, according to the analysis.

    For all that trouble, a woman taking Addyi can expect to gain one-half of one additional satisfying sexual event per month, on average, according to the report. It was published online Feb. 29 in the journal JAMA Internal Medicine.

    "We found women had, on average, 2.5 satisfying sexual events per month before entering the study, and flibanserin added one-half additional satisfying sexual events per month," said senior study author Ellen Laan, a professor of sexology and psychosomatic gynecology at the University of Amsterdam, in the Netherlands.

    The side effects are troubling, said Dr. Mamta Mamik, an assistant professor of obstetrics, gynecology and reproductive science at Mount Sinai's Icahn School of Medicine in New York City.

    "The article is pretty comprehensive in addressing the issues. They raise valid concerns," Mamik said. "I think we have to be careful when a drug is marketed before its safety profile is approved and proper trials have been conducted."

    The U.S. Food and Drug Administration approved Addyi last year after a contentious review process, making it the nation's first drug designed to help women with low libido.

    Only 227 prescriptions for the drug were filled in its first few weeks on the market, Bloomberg reported.

    In the new review, Laan and her colleagues reviewed eight clinical trials conducted with Addyi, including five published and three unpublished studies involving almost 6,000 women.

    The combined evidence showed that Addyi provides marginal benefit for women who are suffering hypoactive sexual desire disorder, a condition involving a persistent or recurrent lack of interest in sex.

    For example, women taking the drug scored just 0.3 points higher on a 5-point sexual desire scale and experienced a minimal increase in satisfying sexual events each month, the review authors found.

    1 | 2 | 3

    Today on WebMD

    couple kissing
    See pictures and get the facts.
    husband taking prescription painkillers
    13 things that can kill your sex drive.
    close up of cold sore
    How to stop them from spreading.
    Condom Quiz
    What are the symptoms?

    HIV Myth Facts
    STD Overview
    Man tearing a condom packet
    things your guy wish you knew slideshow

    Thoughtful man sitting on bed
    Girls Puberty 10
    Couple in bed
    Young couple holding hands